U.S. FDA Issues Warning Letter To Lupin Citing Manufacturing Deficiencies; Warns Products Will Not Be Approved Until Corrective Action

MUMBAI - U.S. FDA issued a May 7 warning letter to Indian drug maker Lupin, that points at several unanswered issues raised by the drug regulator in earlier inspections at the company's Mandideep-based plant in India